How These Healthcare Stocks are Faring? -- GlaxoSmithKline, Universal Health Services, Shire, and LifePoint Health

Friday, March 31, 2017 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 31, 2017 /PRNewswire/ --

Pre-market, revisits the Healthcare sector, which consists

of companies engaged in the manufacture of medical equipment, supplies and pharmaceuticals, as well as the operation of healthcare facilities and provision of managed healthcare. Lined up for assessment are: GlaxoSmithKline PLC (NYSE: GSK), Universal
Health Services Inc. (NYSE: UHS), Shire PLC (NASDAQ: SHPG), and LifePoint Health Inc. (NASDAQ: LPNT). Register now and get full and free access to our downloadable research reports on these stocks at:


On Thursday, shares in Brentford, the UK headquartered GlaxoSmithKline PLC recorded a trading volume of 2.62 million shares. The stock ended at $42.48, declining 0.59% from the last trading session. The Company's shares have gained 2.66% in the last one month, 12.88% over the previous three months, and 11.86% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.84% and 4.92%, respectively. Furthermore, shares of GlaxoSmithKline, which engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide, have a Relative Strength Index (RSI) of 65.91.

On March 09th, 2017, research firm Liberum initiated a 'Buy' rating on the Company's stock.

On March 15th, 2017, GlaxoSmithKline announced the submission of a supplemental Biologics License Application to the US Food and Drug Administration for FLUARIX® QUADRIVALENT (Influenza Vaccine). The submission seeks an expanded indication for children six months through 35 months of age. With this approval, providers would be able to use the same dose of FLUARIX® QUADRIVALENT (15 ug of hemagglutinin per virus strain in 0.5 ml) to cover all eligible persons from six months and up. Access our complete research report on GSK for free at: 

Universal Health Services

King of Prussia, Pennsylvania headquartered Universal Health Services Inc.'s stock finished yesterday's session 0.88% higher at $125.66 with a total trading volume of 585,162 shares. The Company's shares have gained 0.08% in the last one month, 18.48% over the previous three months, and 18.22% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.30% and 3.24%, respectively. Furthermore, shares of Universal Health Services, which through its subsidiaries, owns and operates acute care hospitals, behavioral health facilities, and ambulatory centers, have an RSI of 62.49.

On March 27th, 2017, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $138 per share. The complimentary research report on UHS can be downloaded at: 


At the close of trading on Thursday, shares in Dublin, Ireland headquartered Shire PLC saw a slight decline of 0.48%, ending the day at $177.34. The stock recorded a trading volume of 743,996 shares. The Company's shares have advanced 6.12% in the previous three months and 4.53% since the start of this year. The stock is trading 1.88% above its 50-day moving average. Moreover, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 51.80.

On March 09th, 2017, research firm Liberum initiated a 'Buy' rating on the Company's stock.

On March 30th, 2017, Shire announced that its partner in Japan, Shionogi & Co., Ltd has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market INTUNIV. INTUNIV is a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder, a common psychiatric disorder in children and adolescents. Register for free on and get access to the latest PDF format report on SHPG at: 

LifePoint Health

Brentwood, Tennessee-based LifePoint Health Inc.'s shares ended the day 3.20% higher at $66.15. A total volume of 909,698 shares was traded, which was above their three months average volume of 421,510 shares. The stock has gained 2.88% in the last month, 14.55% over the previous three months, and 16.46% on an YTD basis. The Company's shares are trading 6.46% above their 50-day moving average and 9.88% above their 200-day moving average. Additionally, shares of LifePoint Health, which through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the US, have an RSI of 68.38.

On March 27th, 2017, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $57 a share to $62 a share. Download your free research report on LPNT at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store